Streptococcus pneumoniae (S. pneumoniae) is a major pathogen of bacterial pneumonia, meningitis, sinusitis and otitis media. Antimicrobial resistance in S. pneumoniae, including macrolide resistance, has been a growing problem in recent years due to the increasing numbers of cases with treatment failures of infections caused by macrolide-resistant pneumococci (1).
MICs of macrolides (erythromycin, clarithromycin and azithromycin), lincosamides (clindamycin), streptogramins (quinupristin-dalfopristin) and penicillin G were measured by E-test (AB Biodisk; Solna, Sweden). The strain S. pneumoniae ATCC 49619 was used as a control strain.
Detection of erythromycin-resistance genes
A PCR method was used for the detection of erythromycinresistance genes (5) . Bacterial DNA was isolated using a DNA isolation kit (Roche Diagnostic; Mannheim, Germany). All PCR mixtures contain a volume of 25 µL with 5µL of target DNA, 0.5 µL of each primer (25 mM), 1.5 µL of 25 mM MgCl 2 , 0.5 µL of dNTP mixture (25 mM each), 0.125 µL of Taq DNA polymerase (5 U/µL) and 2.5 µL of 10X buffer (MBI; Fermentas, Lithuania). PCR for both genes was performed on PTC-200 (Peltier Thermal Cycler; MJ Research, USA). Cycling conditions for amplification were: 5 min at 94°C, followed by 40 cycles of 1 min at 94°C, 1 min at 48°C and 1.5 min at 72°C, with a final 10 min incubation at 72°C. PCR products were separated on ethidium bromide stained 1.5% agarose gels. The expected sizes of amplification products for erm (B) and mef (A) were 639 bp and 348 bp, respectively.
The positive control strains were ATCC 700673 (Hungary 
BOX-PCR
DNA amplifications for BOX-PCR were performed in 25 µl final volumes with 5 µL of purified bacterial DNA, 1.5 µL of primer AR1 (CTACGGCAAGGCGACGCTGACG) (25 mM), 1.5 µL of MgCl 2 (25 mM), 0.75 µLof dNTPs (25 mM), 0.125 µL of Taq DNA polymerase (5 U/µL) and 2.5 mL of 10X reaction buffer (6) .
After the initial denaturation at 95°C for 5 min, this step was followed by 30 cycles of 1 min at 90°C, 1 min at 52°C, and 2 min at 72°C, with a final extension at 72°C for 5 min (7). Amplification products were run on 1.5% agarose gels and detected by staining with ethidium bromide. The band patterns were converted to series of 1s and 0s where 1s indicates the presence and 0s the absence of any band.
The analysis of BOX-PCR results and the phylogenetic analysis were performed using FreeTree and TreeView software packages (8, 9) .
RESULTS
Of the total 80 isolates, 22.5% (18/80) were resistant to erythromycin, azithromycin and clarithromycin. Twenty percent of strains were clindamycin-resistant and four (5%) strains had quinupristin-dalfopristin intermediate resistance. According to Clinical Laboratory Standards Institute (CLSI) criteria, penicillin resistance in S. pneumoniae isolates was found to be 7.5% (6/80) and the intermediate resistance rate was 20% (16/80) for oral penicillin criteria. Penicillin intermediate resistance was found to be 2.5% (2/80) for non-meningitis parenteral penicillin criteria. No meningeal isolate was included in the study. Tetracycline, levofloxacin and trimethoprim-sulphomethoxazole resistance rates were as follows: 18.75%, 1.25% and 62.5%, respectively.
According to the erythromycin-clindamycin double-disk test, 16 (88.8%) of the 18 test strains had the cMLS B phenotype and two (11.2%) strains possessed the M phenotype.
PCR of the 18 macrolide-resistant S. pneumoniae strains showed that 44.4% (n=8) strains harbored only the erm (B) gene and 11.2% (n=2) only the mef (A) gene. Eight (44.4%) strains were positive for both the erm (B) and mef (A) genes ( Figure 1 and 2 ). All erm (B) and erm (B)+mef (A) positive strains were resistant to erythromycin, clarithromycin, azithromycin and clindamycin, while mef (A) positive strains had lower erythromycin, clarithromycin and azithromycin MICs and remained susceptible to clindamycin (Table 1) . 
BOX-PCR
Through DNA fingerprint analysis by BOX-PCR, seven clones were identified among 18 macrolide-resistant strains. All of the erm (B) and mef (A) positive isolates were shown to belong to a single clone. The eight strains carrying erm (B) were grouped into four clones. Two mef (A) carrying strains were unrelated (Figure 3 and 4) .
Among erythromycin-susceptible S. pneumoniae strains, the penicillin resistance rate was very low (5 isolates were intermediate and only one strain was fully resistant). In contrast, only two of the 18 erythromycin-resistant isolates were penicillin susceptible. All erm (B) and mef (A) positive strains were penicillin-resistant according to oral criteria; two of these strains showed intermediate resistance according to non-meningitis parenteral penicillin criteria. Three of the four quinupristin-dalfopristin intermediate resistance isolates were positive for erm (B)+mef (A) genes.
DISCUSSION
Macrolide resistance rates among pneumococci have increased over the last two decades. Reported resistance rates were high among strains isolated in the Far East (80%) and South Africa (54%). Low rates were reported from South America (15%), Australia (18%) and Northern Europe (18%). In Europe, the highest resistance rate was reported in France and Greece (10) . In Turkey, macrolide resistance among S. pneumoniae has increased from 7% to 29% (11) (12) (13) (14) (15) . Although Telli et al. (16) reported higher percentages (40%) in 2007-2009, the macrolide resistance rate in this study was 22.5%, which is similar to the result of EARRSS, but higher than the rates reported previously in our hospital (13, 14) . S2 S3 S11 S13 S18 S6 S15 S16 S17 S4 0.1 0.2 (17) . In Germany, Bley et al. (18) reported the presence of combined erm (B)+mef (A) genotype in 4.1% of pneumococcal isolates. Similar results have been increasingly reported in North America, South Asia and South Africa during the last decade (17, 19) . In Russia, dual resistance genes among isolates collected between 2003 and 2005 were found in 30.3% (20) . In China, McGee et al. (21) found both the erm and mef genes in 6% of isolates. In South Africa, the percentage of strains possessing the resistance genes erm and mef was 30.5% in 2001 and 30 (83%) of them belonged to a single, multi-resistant clone (19) . In the USA, Di Persio et al. (22) reported that 71% of macrolide-resistant pneumococci possessed dual resistance genes. Among these strains, two predominant and possibly related clones were detected. A study in Arizona revealed that 23.6% of 592 clinical isolates were macrolide-resistant from 1999 to 2008. More than 50% of the macrolide-resistant population were erm (B)+mef (A) positive (23) . In Canada, erm (B) and mef (A) positive isolates represent 4% in 1998 and 12% in 2004 and one major cluster containing 36 (72%) of the 50 isolates was described (24) .
The percentage of isolates positive for erm(B)+mef(A) genotype is increasing and this is a serious public health problem
In Turkey, Şener et al. (25) in Aydın, Turkey; of these, 74%, 14% and 9% were the cMLS B phenotype, the M phenotype and the iMLS B phenotype, respectively. In addition, 20% were found to be erm (B)+mef (A) positive. No clonal dissemination was found according to PFGE analysis.
In conclusion, this study show that the macrolide resistance of S. pneumoniae isolates is relatively high and the cMLS B phenotype is the most prevalent resistance mechanism in our hospital. The percentage of isolates harboring both erm (B) and mef (A) genes is the highest reported from the studies conducted in our country to date. Dual erm (B) and mef (A) positive isolates tended to have higher resistance rates against penicillin and quinupristin-dalfopristin. In this study, we also showed the clonal relationship among macrolide-resistant S. pneumoniae strains possessing both erm (B) and mef (A) in Turkey for the first time.
